for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BioXcel Therapeutics Inc

BTAI.OQ

Latest Trade

6.24USD

Change

0.00(0.00%)

Volume

8,617

Today's Range

6.18

 - 

6.42

52 Week Range

2.41

 - 

12.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
6.24
Open
6.20
Volume
8,617
3M AVG Volume
1.25
Today's High
6.42
Today's Low
6.18
52 Week High
12.00
52 Week Low
2.41
Shares Out (MIL)
18.04
Market Cap (MIL)
112.54
Forward P/E
-2.54
Dividend (Yield %)
--

Latest Developments

More

BioXcel Therapeutics Inc Affirms Expected Timeline Regarding Upcoming Milestones

BioXcel Therapeutics Announces Pricing Of Public Offering Of Common Stock

Bioxcel Therapeutics Announces Proposed Public Offering Of Common Stock

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About BioXcel Therapeutics Inc

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company that is focused on the development of drugs for psychiatric disorders and rare cancers. The Company uses novel artificial intelligence (AI) for drug re-innovation processes of approved product candidates to identify new therapeutic indices. Its principal clinical development programs are BXCL501 and BXCL701. BXCL501 is a sublingual thin film formulation of dexmedetomidine (Dex) designed for the acute treatment of agitation resulting from neurological and psychiatric disorders. BXCL701 is an immuno-oncology agent designed for the treatment of prostate and pancreatic cancer.

Industry

Biotechnology & Drugs

Contact Info

555 Long Wharf Dr

+1.203.6438060

http://www.bioxceltherapeutics.com/

Executive Leadership

Peter Mueller

Independent Chairman of the Board

Vimal Mehta

President, Chief Executive Officer, Secretary, Director

Richard I. Steinhart

Chief Financial Officer

Frank D. Yocca

Chief Scientific Officer

Vincent J. O'Neill

Chief Medical Officer

Key Stats

1.80 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019(E)

0.0K
EPS (USD)

2018

-1.320

2019(E)

-2.454
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
3.89
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-72.64
Return on Equity (TTM)
-64.66

Latest News

Latest News

BRIEF-Artemis Investment Management LLP Reports 7.74 pct Passive Stake In Bioxcel Therapeutics Inc As Of March 12

* ARTEMIS INVESTMENT MANAGEMENT LLP REPORTS 7.74 PERCENT PASSIVE STAKE IN BIOXCEL THERAPEUTICS INC AS OF MARCH 12, 2018 - SEC FILING Source text - (http://bit.ly/2DpqQcH) Further company coverage:

BRIEF-Bioxcel Therapeutics Sees IPO Of 5.0 Mln Shares Of Common Stock Priced Between $11.00 And $13.00 Per Share

* BIOXCEL THERAPEUTICS INC SEES IPO OF 5.0 MILLION SHARES OF COMMON STOCK PRICED BETWEEN $11.00 AND $13.00 PER SHARE - SEC FILING

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up